{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T10:33:55Z","timestamp":1745922835084,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Iten-Kohaut-Foundation, University Hospital Zurich Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12105-021-01297-6","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T15:19:59Z","timestamp":1612538399000},"page":"1082-1084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["High\u2010grade Salivary Gland Adenocarcinoma Harboring ETV6-NTRK3\u00a0Fusion: Defined by Morphology or Molecular Aberration?"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7043-3456","authenticated-orcid":false,"given":"Niels J.","family":"Rupp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constanze","family":"Nemes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth J.","family":"Rushing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard F.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra N.","family":"Freiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"1297_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12105-020-01140-4","volume":"14","author":"E Todorovic","year":"2020","unstructured":"Todorovic E, Dickson BC, Weinreb I. Salivary gland cancer in the era of routine next-generation sequencing. Head Neck Pathol. 2020;14:311\u201320. https:\/\/doi.org\/10.1007\/s12105-020-01140-4.","journal-title":"Head Neck Pathol"},{"key":"1297_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","volume":"34","author":"A Sk\u00e1lov\u00e1","year":"2010","unstructured":"Sk\u00e1lov\u00e1 A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599\u2013608. https:\/\/doi.org\/10.1097\/PAS.0b013e3181d9efcc.","journal-title":"Am J Surg Pathol"},{"key":"1297_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/1066896917709350","volume":"25","author":"NA Cipriani","year":"2017","unstructured":"Cipriani NA, Blair EA, Finkle J, et al. Salivary gland secretory carcinoma with high-grade transformation, CDKN2A\/B loss, distant metastasis, and lack of sustained response to crizotinib. Int J Surg Pathol. 2017;25:613\u20138. https:\/\/doi.org\/10.1177\/1066896917709350.","journal-title":"Int J Surg Pathol"},{"key":"1297_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/PAS.0000000000000088","volume":"38","author":"A Sk\u00e1lov\u00e1","year":"2014","unstructured":"Sk\u00e1lov\u00e1 A, Vanecek T, Majewska H, et al. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, \u03b2-catenin, EGFR, and CCND1 genes. Am J Surg Pathol. 2014;38:23\u201333. https:\/\/doi.org\/10.1097\/PAS.0000000000000088.","journal-title":"Am J Surg Pathol"},{"key":"1297_CR5","first-page":"9008","volume":"7","author":"W Luo","year":"2014","unstructured":"Luo W, Lindley SW, Lindley PH, et al. Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature. Int J Clin Exp Pathol. 2014;7:9008\u201322.","journal-title":"Int J Clin Exp Pathol"},{"key":"1297_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/PAI.0000000000000320","volume":"24","author":"F Petersson","year":"2016","unstructured":"Petersson F, Michal M, Grossmann P. A new hitherto unreported histopathologic manifestation of mammary analogue secretory carcinoma: \u201cMasked MASC\u201d associated with low-grade mucinous adenocarcinoma and low-grade in situ carcinoma components. Appl Immunohistochem Mol Morphol. 2016;24:6.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1297_CR7","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/PAS.0000000000001301","volume":"43","author":"A Sk\u00e1lov\u00e1","year":"2019","unstructured":"Sk\u00e1lov\u00e1 A, Pt\u00e1kov\u00e1 N, Santana T, et al. NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is intraductal correct? Am J Surg Pathol. 2019;43:1303\u201313. https:\/\/doi.org\/10.1097\/PAS.0000000000001301.","journal-title":"Am J Surg Pathol"},{"key":"1297_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12105-013-0456-x","volume":"7","author":"RHW Simpson","year":"2013","unstructured":"Simpson RHW. Salivary duct carcinoma: new developments\u2014morphological variants including pure in situ high grade lesions; proposed molecular classification. Head Neck Pathol. 2013;7:48\u201358. https:\/\/doi.org\/10.1007\/s12105-013-0456-x.","journal-title":"Head Neck Pathol"},{"key":"1297_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/his.14251","author":"C Taverna","year":"2020","unstructured":"Taverna C, Ban\u011b\u010dkov\u00e1 M, Lorenzon M, et al. MUC4 is a valuable marker for distinguishing secretory carcinoma of the salivary glands from its mimics. Histopathology. 2020. https:\/\/doi.org\/10.1111\/his.14251.","journal-title":"Histopathology"},{"key":"1297_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00428-019-02640-7","volume":"476","author":"D Bell","year":"2020","unstructured":"Bell D, Ferrarotto R, Liang L, et al. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020;476:295\u2013305. https:\/\/doi.org\/10.1007\/s00428-019-02640-7.","journal-title":"Virchows Arch"},{"key":"1297_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731\u201347. https:\/\/doi.org\/10.1038\/s41571-018-0113-0.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-021-01297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-021-01297-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-021-01297-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T19:31:48Z","timestamp":1629833508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-021-01297-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1297"],"URL":"https:\/\/doi.org\/10.1007\/s12105-021-01297-6","relation":{},"ISSN":["1936-0568"],"issn-type":[{"type":"electronic","value":"1936-0568"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"12 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"NJR discloses an advisory board function and receipt of honoraria from F. Hoffmann-La Roche AG. The \u201cSalvGlandDx\u201d panel has been developed by a grant from the Iten-Kohaut-Foundation\/University Hospital Zurich Foundation to NJR. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient provided a written informed consent in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}